Analysis of Single Respiratory Viral Infections Versus Co-infections: Prevalence and ICU Needs in Hospitalized Adults

Kocaeli University231 enrolled

Overview

The objective of our study is to investigate the prevalence of viral respiratory infections in inpatients following the end of the pandemic. Additionally, the prevalence of patients co-infected with multiple viruses simultaneously will be assessed. In the secondary part of the study, the development of respiratory tract infections, the need for intensive care, and mortality rates within seven days will also be evaluated, and risk factors for patients with a more severe clinical course will be statistically calculated.

This study aims to determine the prevalence of viral respiratory agents in hospitalized patients post-COVID-19 and to examine the clinical course of respiratory viral co-infections, which are expected to be more severe. This study will be conducted retrospectively at Kocaeli University Hospital between May 2023, considered the end date of the pandemic, and January 2024. Patients over 18 years of age will be included, and data will be accessed through the hospital automation system. Patients with SARS-CoV-2 PCR-positive symptoms and those expected to use molnupiravir due to the need for treatment will be considered as COVID-19. Respiratory tract agents will be detected by multiplex PCR from symptomatic inpatients. All patients with influenza will also receive oseltamivir. The distribution of viruses, the need for intensive care hospitalization, and whether they cause death within seven days, as well as the prevalence, clinical course, and risk factors of viral co-infections expected to be clinically more severe in the literature, will also be examined

Study Type

OBSERVATIONAL

Enrollment

231

Conditions

Respiratory Tract Infections Virus Diseases Coinfection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 18 years of age * Patients admitted to our clinic or consulted to infectious diseases from other inpatient services. * Patients diagnosed with upper or lower respiratory tract infections due to viral agents Exclusion Criteria: * Patients infected with bacterial agents will not be included in the study. * Patients admitted from the outpatient clinic were not included in the study plan.

Outcomes

Primary Outcomes

Prevalence of Single and Co-infections in Respiratory Viral Infections

Objective: To determine the prevalence of single respiratory viral infections and co-infections in hospitalized adults after COVID-19 pandemic. Assessment Tool: Hospital automation system for patient demographic and clinical data, and multiplex PCR testing for pathogen detection. Unit of Measure: Percentage of patients with each viral infections

Time frame: On 12 January 2025, the retrospective analysis of patients was started. The study is expected to be completed within 3 months.

Secondary Outcomes

Risk Factors and Rates of ICU Admission and Mortality in Respiratory Viral Infections

Objective: To assess the risk factors for ICU admission and seven-day mortality in patients with respiratory viral infections Assessment Tool: Patient records for ICU admission and mortality data, combined with statistical analysis to identify risk factors. Unit of Measure: Odds ratios for ICU admission and mortality.